Related Experiment Video
Updated: Dec 24, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
Kenichiro Kudo1, Keita Kawakado1, Tomoka Kawajiri1
1Department of Respiratory Medicine, Iwakuni Clinical Center, Japan.
Abstract:
The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutation-positive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.
Insights
Dacomitinib shows promise for treating brain metastases in elderly patients with EGFR-mutant non-small-cell lung cancer (NSCLC). This case report suggests dacomitinib is a viable option for managing brain metastases in this patient group.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) is a significant cause of cancer-related mortality.
- Brain metastases are a common and serious complication of NSCLC, impacting patient prognosis and quality of life.
- The efficacy of dacomitinib, an EGFR tyrosine kinase inhibitor, specifically within the central nervous system (CNS) for NSCLC with brain metastases remains incompletely understood.
Observation:
- This case report details the treatment of an elderly patient with multiple brain metastatic lesions originating from EGFR-mutation-positive NSCLC.
- The patient received dacomitinib as a therapeutic intervention for their brain metastases.
- The clinical course and response to dacomitinib were closely monitored.
Findings:
- Dacomitinib demonstrated efficacy in managing brain metastatic lesions in this elderly patient with EGFR-mutant NSCLC.
- The treatment was associated with positive outcomes regarding the central nervous system (CNS) disease burden.
- This observation suggests potential anti-tumor activity of dacomitinib within the brain.
Implications:
- Dacomitinib may represent an essential treatment option for elderly patients with EGFR-mutant NSCLC and brain metastases.
- Further clinical investigation is warranted to confirm the CNS efficacy and safety profile of dacomitinib in this specific patient population.
- These findings could influence treatment strategies for NSCLC patients with advanced disease and intracranial involvement.
